Thermo Fisher: the lab-tools compounder still has to prove the biopharma cycle is healing
Thermo Fisher reported 2025 revenue of $44.6 billion and Q1 2026 revenue of $11.0 billion. The thesis depends on biopharma demand, instrument and consumables mix, diagnostics normalization, margin durability, M&A integration and cash conversion.
Open